Organization (Other)
Par Pharmaceutical, Inc.
ClinicalTrials.gov lists Par Pharmaceutical, Inc. as lead sponsor of 36 trials. It has 20 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Par Pharmaceutical, Inc.: 36 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dyslipidemias | 11 |
| Hypoalphalipoproteinemias | 11 |
| Lecithin Cholesterol Acyltransferase Deficiency | 11 |
| Anorexia | 2 |
| Cachexia | 2 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2013 | 2 |
| 2006 | 4 |
| 2005 | 3 |
| 2004 | 4 |
| 2003 | 4 |
| 2002 | 6 |
| 2001 | 4 |
| 2000 | 1 |
| 1999 | 5 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 36 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (20)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PROPRANOLOL | 2 |
| Doxycycline | 5 |
| Ondansetron | 4 |
| ORACEA® | 3 |
| Zofran | 3 |
Showing 5 of 20 approved assets.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 45 | 7 | 2025-01-07 |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| PRA Health Sciences | Uses vendor | 2 |
| Covance (United States) | Uses vendor | 1 |
| SFBC Anapharm | Co sponsors trial with | 1 |
Latest dated events (81)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-01-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-01-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-10-10 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-08-08 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-03-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 81 events.
Biomarker capability evidence (8)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| GGT1 | Trial sponsor | Named in trial inclusion criteria |
| GGT1 | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Mentioned in trial text |
Showing 5 of 8 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, journals published in, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.